Smolen JS, Steinberg ADSystemic lupus erythematosus and pregnancy: clinical, immunological, and theoretical aspects. Progr ClinBiol Res1981; 70: 283-302.
4.
Russell DH, Kibler R., Matrisian L., Lanson DF, Poulos B., Magun BEProlactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine. J Immunol1985; 134: 3027-31.
5.
Clevenger CV , Russell DH, Appasamy PM, Prystowsky MBRegulation of interleukin 2-driven T-lymphocyte proliferation by prolactin. Proc Natl Acad Sci USA1990; 87: 6460-4.
6.
Hartmann DP, Holaday JW, Benton EWInhibition of lymphocyte proliferation by antibodies to prolactin . FASEB J1989; 3: 2194-202.
7.
Cross RJ, Campbell JL, Roszman TLPotentiation of antibody responsiveness after the transplantation of a syngeneic pituitary gland. J Neuroimmunol1989; 25: 29-35.
8.
Berczi I., Nagy E., Asa SL, Kovacs K.The influence of pituitary hormones on adjuvant arthritis. Arthritis Rheum1984; 27: 682-8.
9.
Jara-Quezada L., Graef A., Lavalle C.Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus. J Rheumatol1991 ; 18: 349-53.
10.
Jara LJ, Gomez-Sanchez C., Silveira LH et al. Hyperprolactinemia in systemic lupus erythematosus. Am J Med Sci1992; 303: 222-6.
11.
McMurray RW , Allen SH, Braun A., Walker SELongstanding hyperprolactinemia associated with systemic lupus erythematosus: possible hormonal stimulation of an autoimmune syndrome. Arthritis Rheum1992; 35 (Suppl): S168 (abstract C8).
12.
McMurray RW, Allen SH, Braun A., Walker SELongstanding hyperprolactinemia associated with systemic lupus erythematosus: possible hormonal stimulation of an autoimmune disease. (submitted for publication)
13.
McMurray R. , Keisler D., Kanuckel K., Izui S., Walker SEThe influence of prolactin on disease activity in the female B/W mouse. J Immunol1991; 147: 3780-7.
McMurray RW , Hoffman RW, Walker SEIn vivo prolactin manipulation alters in vitro IL-2, IL-4, and IFN-γ mRNA levels in female B/W mice. Clin Res1991; 39: 734A (abstract).
16.
Kishimoto T. , Hirano T.Molecular regulation of B lymphocyte response . Ann Rev Immunol1988 ; 6: 485-512.
17.
Prud'homme GJ, Park CL, Fieser TM, Kofler R., Dixon FJ, Theofilopoulos ANIdentification of a B cell differentiation factor(s) spontaneously produced by proliferating T cells in murine lupus strains of the lpr/lpr genotype. J Exp Med1983;157: 730-42.
18.
Linker-Israeli M., Deant R.Dysregulated lymphokine production in systemic lupus erythematosus (SLE). Ann NY Acad Sci1989; 557: 567-9.
19.
Alcocer-Varela J., Aleman-Hoey D., Alarcon-Segovia D.Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers. Lupus1992; 1: 111-7.
20.
Melez KA, Boegel WA, Steinberg ADTherapeutic studies in New Zealand mice. VII. Successful androgen treatment of NZB/NZW F1 females of different ages. Arthritis Rheum1980; 12: 41-7.
21.
Jungers P., Nahoul K., Pelissier C., Dougados M., Tron F., Bach JFLow plasma androgens in women with active or quiescent systemic lupus erythematosus . Arthritis Rheum1982; 25: 454-7.
22.
Lahita RG, Bradlow HL, Ginzler E., Pang S., New M.Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum1987; 30: 241-8.
23.
Lavalle C., Loyo E., Paniagua R. et al. Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus. J Rheumatol1987; 14:268-72.
24.
Inman RD, Jovanovic L., Markenson JA, Longcope C., Dawood MY, Lockshin MDSystemic lupus erythematosus in men. Genetic and endocrine features . Arch Intern Med1982; 142: 1813-5.
25.
Lavalle C., Gonzalez-Barcena D., Graef A., Fraga A.Gonadotropins pituitary secretion in systemic lupus erythematosus . Clin Exp Rheum1984; 2: 163-5.
26.
McMurray RW, Keisler D., Izui S., Walker SEHyperprolactinemia (Hyper PR) accelerates disease activity in the male NZB/W mouse model of SLE. Arthritis Rheum1991; 34(Suppl): S163 (abstract C182).
27.
Hazelton RA, McCruden AB, Sturrock RD, Stimson WHHormonal manipulation of the immune response in systemic lupus erythematosus: a drug trial of an anabolic steroid, 19-nortestosterone. Ann Rheum Dis1983; 42: 155-7.
28.
Agnello V., Pariser K., Gell J., Gelfand J., Turksoy RNPreliminary observations on Danazol therapy of systemic lupus erythematosus: effects on DNA antibodies, thrombocytopenia and complement. J Rheumatol1983; 10: 682-7.
29.
Lahita RG, Cheng CY, Monder C., Bardin CWExperience with 19-nortestosterone in the therapy of systemic lupus erythematosus: worsened disease after treatment with 19-nortestosterone in men and lack of improvement in women. J Rheumatol1992; 19: 547-55.
30.
Rabinovich CE, Schanberg L., Kredich D.Intravenous immunoglobulin and bromocriptine in the treatment of refractory neuropsychiatric SLE. Arthritis Rheum1990; 33(Suppl): R22 (abstract 49S).
31.
Molitch ME, Russell EJThe pituitary 'incidentaloma'. Ann lnt Med1990; 112: 925-31.
32.
Pauzner R., Urowitz MB, Gladman DDProlactin levels in systemic lupus erythematosus (SLE). Arthritis Rheum1992; 35(Suppl): S239 (abstract D156).
33.
Vankelecom H., Carmeliet P., Damme JV, Billiau A., Denef C.Production of interleukin-6 by folliculo-stellate cells of the anterior pituitary gland in a histiotypic cell aggregate culture system. Neuroendocrinology1989; 49: 102-6.
34.
Jones TH, Price A., Justice S., Chapman K.Interleukin-6 secretion by human pituitary adenomas in vitro. J Endocrinol1990; 127(Suppl): 86 (abstract 86).
35.
Melez KA, Boegel WA, Steinberg ADTherapeutic studies in New Zealand mice. VII. Successful androgen treatment of NZB/ NZW F1 females of different ages. Arthritis Rheum1980; 12: 41-7.
